Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05907694

Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure

Led by Josep Rodes-Cabau · Updated on 2026-03-27

714

Participants Needed

2

Research Sites

693 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Patent foramen ovale PFO closure has been shown to reduce the risk of stroke in patients with recurrent stroke. However, the majority of existing clinical studies in this field excluded patients over the age of 60 years. Data in older patients is limited and since the population ages and stroke remains a major cause of death and morbidity, randomized clinical trials are needed to better assess the benefit of PFO closure in this elderly population. Therefore, this study proposal sought to determine the efficacy of PFO closure for the prevention of recurrent stroke in older patients with PFO and cryptogenic stroke.

CONDITIONS

Official Title

Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Cryptogenic stroke
  • Age >60 years
  • Right-to-left shunt as evaluated by echocardiography (TEE).
Not Eligible

You will not qualify if you...

  • Age ≤60 years
  • Lacunar (small vessel) stroke
  • Permanent or paroxysmal atrial fibrillation/flutter (clinically apparent or detected by continuous ECG monitoring)
  • Need for chronic anticoagulation therapy
  • Any contraindication for antiplatelet therapy (aspirin, clopidogrel, ticagrelor)
  • Presence of extracranial or intracranial atherosclerosis causing ≥50% luminal stenosis in arteries supplying the area of ischemia
  • Presence of complex atheroma plaques at the ascending aorta-aortic arch (≥4-mm-thick, ulcerated or containing mobile thrombi) as evaluated by TEE
  • Presence of intracardiac thrombus as evaluated by TEE
  • Uncontrolled hypertension (systemic pressure values >160/90 mmHg despite optimal medical treatment)
  • History of myocardial infarction or coronary intervention (percutaneous coronary intervention, coronary artery bypass graft)
  • History of prior valve surgery or transcatheter valve repair
  • Presence of deep venous thrombosis at the time of index stroke as evaluated by Doppler ultrasonography
  • Left ventricular ejection fraction <50% as evaluated by TTE
  • Significant (moderate or severe) valvular disease as evaluated by echocardiography
  • History of congestive heart failure
  • Severe chronic kidney dysfunction defined an estimated glomerular filtration rate <30 ml/min/m2 or need for dialysis
  • Isolated ASD or ASD associated with PFO but with a hemodynamically significant left-to-right shunt requiring closure
  • Other specific cause of stroke identified (eg, arteritis, dissection, migraine/vasospasm, and drug abuse)
  • Prior surgical or endovascular treatments of PFO or ASD
  • Rheumatic heart disease
  • Left atrial enlargement defined as a left atrial diameter >41 mm in men and ≥39 mm in women
  • Presence of high burden of premature atrial contractions (>500 per 24 hrs) as evaluated by continuous ECG monitoring
  • Follow-up impossible or expected poor compliance
  • Active cancer
  • Presence of an inferior vena cava filter
  • Severe pulmonary artery hypertension (systolic pulmonary pressure >60 mmHg)
  • Functional dependency as measured by a modified Rankin Scale score >3 (unable to attend to own bodily needs without assistance and unable to walk unassisted)
  • Any medical condition determining a life expectancy <2 years
  • Participation in another randomized study
  • Failure to provide signed informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

IUCPQ-UL

Québec, Quebec, Canada, G1V 4G5

Active, Not Recruiting

2

IUCPQ

Québec, Quebec, Canada, G2E4G9

Actively Recruiting

Loading map...

Research Team

J

Josep Rodes-Cabau, MD, PhD

CONTACT

M

Melanie Cote, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here